SPA
DNA icon

Sherbrooke Park Advisers’s Ginkgo Bioworks DNA Stock Holding History

Sherbrooke Park Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,598
Closed -$169K – 296
2025
Q3 		$169K Buy
11,598
+280
+2% +$3.35K 0.08% 403
2025
Q2 		$127K Sell
11,318
-6,758
-37% -$52.4K 0.06% 438
2025
Q1 		$103K Sell
18,076
-6,206
-26% -$63.2K 0.05% 509
2024
Q4 		$238K Sell
24,282
-23,950
-50% -$205K 0.08% 507
2024
Q3 		$393K Buy
+48,232
New +$483K 0.09% 433

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's DNA Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 11,598 shares — an estimated $169K sold.

Sherbrooke Park Advisers first reported a position in DNA in Q3 2024 and held it in 5 quarters. The position peaked at $393K in Q3 2024. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,598 Ginkgo Bioworks shares in Q4 2025, an estimated $169K.
  • Sherbrooke Park Advisers first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 5 quarters.
  • Sherbrooke Park Advisers's Ginkgo Bioworks position peaked at $393K in Q3 2024.
  • 181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.